Literature DB >> 16107353

How useful is [123I]beta-CIT SPECT in clinical practice?

J Eerola1, P J Tienari, S Kaakkola, P Nikkinen, J Launes.   

Abstract

OBJECTIVE: To assess the accuracy and clinical usefulness of [(123)I]beta-CIT (2beta-carbomethoxy-3beta-(4-iodophenyl)tropane) SPECT in the differential diagnosis of Parkinson's disease.
SUBJECTS: 185 consecutive patients with symptoms of movement disorder were studied. The diagnoses were Parkinson's disease (92), essential tremor (16), vascular parkinsonism (15), various Parkinson plus syndromes (P+) (12), dementia with Lewy bodies (DLB) (5), dystonia (5), drug induced movement disorder (12), and other diagnoses (8). A reference group (psychogenic parkinsonism) comprised 20 subjects with complaints suggesting extrapyramidal disease but with no unequivocal signs on clinical examination and no abnormalities on brain imaging.
RESULTS: beta-CIT uptake was significantly lower in the whole striatum as well as separately in the putamen and in the caudate nucleus in Parkinson's disease than in the reference group or in drug induced movement disorder, essential tremor, or dystonia. The uptake of beta-CIT in the vascular parkinsonism group was heterogeneous and mean beta-CIT uptake fell between the reference group and the Parkinson's disease group. In the P+ and DLB groups the striatal uptake ratios overlapped those of the Parkinson's disease group.
CONCLUSIONS: [(123)I]beta-CIT SPECT may not be as useful a tool in the clinical differential diagnosis of Parkinson's disease as was previously believed, but it was 100% sensitive and specific for the diagnosis in younger patients (age <55 years). In older patients (age >55 years) specificity was substantially lower (68.5%). This differential specificity reflected the different distribution of differential diagnostic disorders (P+, DLB, vascular parkinsonism) in the older and younger age groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107353      PMCID: PMC1739796          DOI: 10.1136/jnnp.2004.045237

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  38 in total

Review 1.  Structure and function of the dopamine transporter.

Authors:  N Chen; M E Reith
Journal:  Eur J Pharmacol       Date:  2000-09-29       Impact factor: 4.432

2.  Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.

Authors:  W Pirker; S Asenbaum; M Hauk; S Kandlhofer; J Tauscher; M Willeit; A Neumeister; N Praschak-Rieder; P Angelberger; T Brücke
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

3.  [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.

Authors:  W Pirker; S Asenbaum; G Bencsits; D Prayer; W Gerschlager; L Deecke; T Brücke
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

4.  Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

Authors:  M Guttman; D Stewart; D Hussey; A Wilson; S Houle; S Kish
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

5.  Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease.

Authors:  G Ransmayr; K Seppi; E Donnemiller; E Luginger; J Marksteiner; G Riccabona; W Poewe; G K Wenning
Journal:  Eur J Nucl Med       Date:  2001-10

6.  The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.

Authors:  J E Ahlskog; R J Uitti; M K O'Connor; D M Maraganore; J Y Matsumoto; K F Stark; M F Turk; O L Burnett
Journal:  Mov Disord       Date:  1999-11       Impact factor: 10.338

7.  [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.

Authors:  A Varrone; K L Marek; D Jennings; R B Innis; J P Seibyl
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

8.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.

Authors:  J Booij; J D Speelman; M W Horstink; E C Wolters
Journal:  Eur J Nucl Med       Date:  2001-03

9.  [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.

Authors:  T H Haapaniemi; A Ahonen; P Torniainen; K A Sotaniemi; V V Myllylä
Journal:  Mov Disord       Date:  2001-01       Impact factor: 10.338

10.  Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.

Authors:  B Jeon; J M Kim; J M Jeong; K M Kim; Y S Chang; D S Lee; M C Lee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

View more
  15 in total

1.  Expert testimony at the Food and Drug Administration: who wants the truth?

Authors:  Joel S Perlmutter
Journal:  Narrat Inq Bioeth       Date:  2011

Review 2.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

Review 3.  PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases.

Authors:  Feng-Mei Lu; Zhen Yuan
Journal:  Quant Imaging Med Surg       Date:  2015-06

4.  [Clinical and imaging diagnostics of Parkinson's disease and multiple system atrophy].

Authors:  K I Schmidt; J Spiegel; W Reith
Journal:  Radiologe       Date:  2011-04       Impact factor: 0.635

5.  Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease.

Authors:  Edna Grünblatt; Sonja Zehetmayer; Christian P Jacob; Thomas Müller; Wolfgang H Jost; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2010-11-11       Impact factor: 3.575

6.  Predictive value of dopamine transporter SPECT imaging with [¹²³I]PE2I in patients with subtle parkinsonian symptoms.

Authors:  Morten Ziebell; Birgitte B Andersen; Gerda Thomsen; Lars H Pinborg; Merete Karlsborg; Steen G Hasselbalch; Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-18       Impact factor: 9.236

7.  The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.

Authors:  Koen Van Laere; Ludwig Everaert; Lieven Annemans; Michel Gonce; Wim Vandenberghe; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-02       Impact factor: 9.236

Review 8.  Neuroimaging findings in children with paediatric neurotransmitter diseases.

Authors:  Wang-Tso Lee; Wen-Chin Weng; Shinn-Forng Peng; Kai-Yuan Tzen
Journal:  J Inherit Metab Dis       Date:  2009-05-20       Impact factor: 4.982

9.  Surface EMG and acceleration signals in Parkinson's disease: feature extraction and cluster analysis.

Authors:  Saara M Rissanen; Markku Kankaanpää; Alexander Meigal; Mika P Tarvainen; Juho Nuutinen; Ina M Tarkka; Olavi Airaksinen; Pasi A Karjalainen
Journal:  Med Biol Eng Comput       Date:  2008-07-17       Impact factor: 2.602

Review 10.  SPECT molecular imaging in Parkinson's disease.

Authors:  Ling Wang; Qi Zhang; Huanbin Li; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.